Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status
- 30 June 2006
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 60 (5) , 534-539
- https://doi.org/10.1136/jcp.2006.039552
Abstract
Background: Expression of mucin antigen MUC1 and down regulation of MUC2 are associated with adverse prognosis in colorectal cancer (CRC), but their prognostic significance with respect to differing DNA mis- match repair (MMR) status is poorly understood. Objective: To determine the prognostic significance of MUC1 and MUC2 in CRC with different MMR statuses. Methods: Using the tissue microarray (TMA) technique, a series of 1420 unselected, non-consecutive CRC resections was subdivided into three groups: (1) MMR-proficient; (2) MLH1-negative; and (3) presumed hereditary non-polyposis colon cancer (HNPCC). Immunohistochemical analysis of MUC1 and MUC2 expression (>0%) and loss (0%) was performed, and the results were correlated with clinicopathological parameters. Results: In MMR-proficient CRC, MUC1 expression was more frequently found in tumours with higher tumour stage (p = 0.004) and higher tumour grade (p = 0.041) and loss of MUC2 was associated with higher tumour stage (p = 0.028), node stage (p = 0.001), presence of vascular invasion (p = 0.028) and worse survival (p = 0.034). In MLH1-negative CRC, MUC2 loss was associated with the presence of lymph node metastasis (p = 0.028) and worse survival (p = 0.015), but there was no association between MUC1 expression and clinicopathological features. In presumed HNPCC, MUC1 expression and MUC2 loss were not associated with clinicopathological parameters. Conclusions: Mucins have a prognostic significance in sporadic CRC, but not in hereditary CRC. Loss of MUC2 is an adverse prognostic factor in MMR-proficient and MLH1-negative CRC, whereas MUC1 expression is associated with tumour progression in MMR-proficient CRC only.Keywords
This publication has 45 references indexed in Scilit:
- Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal–regulated kinase, and phosphorylated AKT in colorectal cancer—A tissue microarray–based approach☆Human Pathology, 2006
- Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl‐Lewisa and sialyl‐Lewisx antigens in colorectal adenocarcinomaHistopathology, 2002
- Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical EndpointsThe American Journal of Pathology, 2001
- Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 2001
- Microarrays of bladder cancer tissue are highly representative of proliferation index and histological gradeThe Journal of Pathology, 2001
- Mucin core proteins as differentiation markers in the gastrointestinal tractHistopathology, 2000
- Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas.2000
- Detecting Activation of Ribosomal Protein S6 Kinase by Complementary DNA and Tissue Microarray AnalysisJNCI Journal of the National Cancer Institute, 2000
- Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectumGut, 2000
- Clinical Significance of MUC1 and MUC2 Mucin and p53 Protein Expression in Colorectal CarcinomaJapanese Journal of Clinical Oncology, 2000